Cribriform carcinoma of the prostate and cribriform prostatic intraepithelial neoplasia: incidence and clinical implications
- PMID: 9669346
- DOI: 10.1097/00000478-199807000-00006
Cribriform carcinoma of the prostate and cribriform prostatic intraepithelial neoplasia: incidence and clinical implications
Abstract
Cribriform neoplasia of the prostate can be recognized easily. However, controversy persists regarding terminology, particularly with the intraductal spread of cribriform neoplasia; some consider this "intraductal carcinoma," whereas consensus meetings defined these lesions as high-grade cribriform prostatic intraepithelial neoplasia (HGCP). This study attempts to identify the incidence and clinical significance of HGCP and cribriform carcinoma (CC) by evaluating 114 radical prostatectomy specimens. Cases were divided into three histologic groups for statistical analysis: (1) pure acinar carcinoma: infiltrating acinar carcinoma without evidence of cribriform neoplasia; (2) CC: acinar carcinoma with CC; and (3) HGCP: acinar carcinoma with HGCP. High-grade cribriform prostatic intraepithelial neoplasia was defined as the presence of neoplastic cells spanning the entire lumen in a cribriform configuration in which a basal cell layer could be shown by immunohistochemistry. Similar areas in which no basal cell layer could be seen were diagnosed as CC. The incidence of cribriform neoplasia was 38% (43 of 114). The incidences of HGCP and CC were 13% (15 of 114) and 25% (28 of 114), respectively. Univariate analysis showed a strong association between HGCP and CC both and several preoperative and final pathology results, including digital rectal examination, pathology tumor stage, extraprostatic extension, surgical margin positivity, high Gleason sum (GS), and high tumor volume. Kaplan-Meier analysis showed HGCP to have a 61% cumulative prostate-specific antigen (PSA) failure rate in contrast with CC and pure acinar cancer, which had cumulative PSA failure rates of 15% and 13%, respectively (p = 0.0001, log-rank test). Multivariate Cox's proportional-hazards analysis found preoperative serum PSA, GS, tumor stage, and volume to be important predictors of PSA failure. In a second regression model that included serum PSA, GS, and pathology tumor stage, HGCP was an independent predictor of PSA failure. Both HGCP and CC are closely associated with several poor prognostic indicators, including advanced pathology tumor stage, a high GS, and serum PSA. Multivariate analysis showed HGCP as an independent prognostic indicator. The close association between high tumor volume and HGCP supports the theory that the development of HGCP is a late event in tumor progression, more compatible with the intraductal spread of tumor than dysplasia.
Similar articles
-
High-grade prostatic intraepithelial neoplasia is an independent predictor of outcome after radical prostatectomy.BJU Int. 2007 Nov;100(5):1066-70. doi: 10.1111/j.1464-410X.2007.07115.x. Epub 2007 Sep 3. BJU Int. 2007. PMID: 17784880
-
Clinicopathological analysis of intraductal proliferative lesions of prostate: intraductal carcinoma of prostate, high-grade prostatic intraepithelial neoplasia, and atypical cribriform lesion.Hum Pathol. 2014 Aug;45(8):1572-81. doi: 10.1016/j.humpath.2014.03.011. Epub 2014 Apr 12. Hum Pathol. 2014. PMID: 24842280
-
Prostatic intraepithelial neoplasia does not appear to raise serum prostate-specific antigen concentration.Urology. 1996 May;47(5):693-8. doi: 10.1016/s0090-4295(96)00004-0. Urology. 1996. PMID: 8650867
-
Repeat biopsy strategy in patients with atypical small acinar proliferation or high grade prostatic intraepithelial neoplasia on initial prostate needle biopsy.J Urol. 2001 Sep;166(3):866-70. J Urol. 2001. PMID: 11490235 Review.
-
High-grade prostatic intraepithelial neoplasia, PIN-like carcinoma, ductal carcinoma, and intraductal carcinoma of the prostate.Mod Pathol. 2018 Jan;31(S1):S71-79. doi: 10.1038/modpathol.2017.138. Mod Pathol. 2018. PMID: 29297491 Review.
Cited by
-
Intraductal carcinoma of prostate: a comprehensive and concise review.Korean J Pathol. 2013 Aug;47(4):307-15. doi: 10.4132/KoreanJPathol.2013.47.4.307. Epub 2013 Aug 26. Korean J Pathol. 2013. PMID: 24009625 Free PMC article. Review.
-
Intraductal carcinoma of the prostate.Pathologica. 2020 Mar;112(1):17-24. doi: 10.32074/1591-951X-5-20. Pathologica. 2020. PMID: 32202536 Free PMC article. Review.
-
Precursor lesions to prostatic adenocarcinoma.Virchows Arch. 2009 Jan;454(1):1-16. doi: 10.1007/s00428-008-0707-5. Epub 2008 Dec 2. Virchows Arch. 2009. PMID: 19048290 Review.
-
Proliferative lesions of prostate: a multivariate approach to differential diagnosis.Pathol Oncol Res. 2005;11(2):103-7. doi: 10.1007/BF02893376. Epub 2005 Jul 1. Pathol Oncol Res. 2005. PMID: 15999155
-
Intraductal Carcinoma of the Prostate versus Simulants: A Differential Diagnosis Growing in Clinical Impact.Cancers (Basel). 2024 Mar 8;16(6):1097. doi: 10.3390/cancers16061097. Cancers (Basel). 2024. PMID: 38539432 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous